Neuronetics Surpasses 1,000 Device Installations in the U.S.

Neuronetics Inc., a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, has delivered more than 2.5 million treatments with its NeuroStar Advanced Therapy transcranial magnetic stimulation (TMS) system, in addition to recently exceeding 1,000 device installations in the United States. These important milestones further demonstrate NeuroStar as a much-needed, non-drug treatment option for adults with Major Depressive Disorder (MDD) that is helping to tackle the country’s critical depression issue.
 
Depression impacts more than 13.3 million adults in the United States, but many do not seek treatment^1,2,3— resulting in a need for accessible, safe, non-drug treatment options that work. Unlike electroconvulsive therapy (ECT), NeuroStar TMS is a non-drug, non-invasive treatment that uses magnetic pulses to stimulate areas of the brain that are underactive in depression.^4,5 Since receiving U.S. Food and Drug Administration clearance in 2008 as a safe and effective treatment for adult patients with MDD, NeuroStar has become a trailblazer in the treatment of depression and is the number one TMS choice of doctors. Now with more than 2.5 million NeuroStar treatments delivered and over 1,000 devices installed across the United States, NeuroStar is available in nearly every state.
 
“These milestones indicate that doctors continue to trust NeuroStar as the number one TMS choice in the country and, as a result, more men and women with depression are getting access to this non-drug treatment that has the potential to be life-changing,” said Dan Guthrie, chief commercial officer of Neuronetics Inc. “We are so proud of how far we’ve come over the last decade, but we know there’s still work to do. We remain committed to transforming lives and ensuring that as many people as possible not only know about NeuroStar as a treatment option, but also have access to it.”
 
The NeuroStar system’s technology offers doctors real-time feedback and delivers precise and accurate targeting that provides reliable and consistent treatment. In an open-label clinical trial, 58 percent of patients significantly responded to treatment and 37 percent achieved complete remission of their depression symptoms with NeuroStar.⁶ Treatment sessions can be performed in as little as 19 minutes**— patients have the flexibility to fit it within their busy lives, and doctors can see more patients, allowing them to provide NeuroStar TMS to a growing patient population.

“After struggling with depression for nearly 20 years, and finding no relief with antidepressants, my doctor and I decided on NeuroStar as my next step, and it changed my life,” said Cara Scruggs, a licensed professional counselor and NeuroStar patient advocate. “From my experience as both a patient and a behavioral healthcare professional, I know how important it is to have access to clinically proven treatment options that can be a catalyst to recovery. Access to NeuroStar TMS made a major positive impact on my life, and I’m grateful that, with these exciting milestones, even more individuals will have an opportunity to experience this proven solution for themselves.”*
 
NeuroStar Advanced Therapy is the market leader in transcranial magnetic stimulation (TMS), a non-invasive form of neuromodulation, and the top TMS choice of doctors for patients with Major Depressive Disorder (MDD). Widely available across the United States, NeuroStar is reimbursed by most commercial and government health plans, including Medicare and Tricare. In the United States, NeuroStar is indicated for the treatment of MDD in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance.
 
In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical-trial version of the NeuroStar TMS System were 4.2 times more likely to achieve remission compared to patients receiving sham treatment (P = 0.02; odds ratio = 4.05).⁷ The most common side effect is pain or discomfort at or near the treatment site, which usually resolves within one week. It is contraindicated in people with non-removable conductive metal in or near the head.
 
* Results may vary
** Treatment time may vary depending on doctor’s recommendation.

References
¹ https://factfinder.census.gov/faces/nav/jsf/pages/index.xhtml, accessed 1/16/2018
² Kessler RC, et al. (2003), JAMA
³ Gaynes BN, et al. (2008), Cleveland Clinic Journal of Medicine
⁴ Post A, et al. (2001),  J Psychiatric Research
⁵ Liston C, et al. (2014), Biol Psychiatry
⁶ Carpenter LL, et al. (2012), Depress Anxiety
⁷ George MS, et al. Arch Gen Psychiatry, (2010)